Alcohol Use Disorder — Recovery and Long-Term Outcomes

A Comprehensive Clinical Knowledge Base

Overview — Recovery Is Real and Common

Recovery from alcohol use disorder (AUD) is not rare. It is not aspirational. For most people who have ever had AUD, improvement over time is the most likely outcome — and that is a fact worth stating plainly at the start.

The best population-level evidence comes from NESARC-III, a nationally representative U.S. survey. Among 7,785 adults who had AUD in the year before the survey, only 34.2% showed persistent AUD at the time of the interview. The rest had improved: 16.0% had achieved abstinent recovery and 17.9% had achieved non-abstinent low-risk recovery ^[1]. Critically, one-quarter of those who recovered did so without any formal treatment. A broader synthesis of epidemiological evidence estimates that approximately 70% of people with AUD improve without formal interventions, with low-risk drinking being the more common outcome in untreated samples ^[2] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication).

These numbers carry two messages that must be held together. First: recovery is common, and many roads lead there. Second: relapse is also common, and it is not the end of the story. A single lapse does not undo recovery. A return to heavy drinking after a period of remission is not a moral failure — it is a clinical event in a chronic condition, and it calls for re-engagement, not despair.

This article synthesizes evidence from a multi-expert panel to give clinicians, researchers, and people affected by AUD the most complete, honest picture of what long-term recovery actually looks like.

Terminology — Recovery, Remission, Abstinence

Precision in language matters here. These terms are not interchangeable, and using them loosely creates confusion for patients, families, and clinicians alike.

Recovery, as formally defined by the NIAAA, requires two things: (1) remission from DSM-5 AUD symptoms (excluding craving) and (2) cessation of heavy drinking ^[3]. Importantly, this definition explicitly permits non-abstinent outcomes. A person who drinks occasionally but never heavily and no longer meets AUD diagnostic criteria can be in recovery. This is a significant departure from older abstinence-only frameworks.

Remission is a DSM-5 term with two specifiers:
- Early remission: No AUD criteria met (except craving) for 3 to 12 months
- Sustained remission: No AUD criteria met (except craving) for 12 months or longer

Abstinent recovery (AR) means no alcohol use at all, combined with AUD remission. Non-abstinent recovery (NAR) means reduced drinking that no longer meets the threshold for heavy use, combined with AUD remission. In NESARC-III data, treatment receipt was markedly higher among those achieving AR (43.2%) than NAR (12.3%), suggesting these are genuinely different pathways with different profiles ^[1].

Lapse refers to a single episode of drinking after a period of abstinence or controlled use. Relapse refers to a sustained return to problematic drinking. These are not the same thing, and the distinction matters enormously for how patients understand their own experience (see the Lapse vs. Relapse section below).

WHO Risk Drinking Levels represent a continuous outcome framework increasingly used in clinical trials. Rather than asking only "did you drink?", this approach measures whether a person moved from a higher-risk drinking category to a lower one — a clinically meaningful change even without full abstinence (see the dedicated section below).

Realistic Trajectories — What the Evidence Shows Over Time

Recovery is rarely a straight line. Most people who eventually achieve sustained remission have a history that includes periods of heavy drinking, periods of reduced drinking, treatment episodes, and lapses. Understanding this is essential for setting realistic expectations without undermining hope.

Short-term outcomes (up to 1 year): Only 22.5% of people who completed formal treatment met full NIAAA recovery criteria at the end of treatment ^[4]. This is not a failure of treatment — it reflects the reality that recovery is a process, not an event. Residual DSM-5 AUD symptoms at 6 months independently predict slips, heavy episodic drinking, and hazardous use at 12 months among older adults, even after controlling for current alcohol use status ^[5]. This means symptom monitoring should continue well past the acute treatment phase.

Medium-term outcomes (1–3 years): Project MATCH data show a clear dose-response relationship between psychotherapy attendance and outcomes. Participants who completed all 12 sessions of CBT or Twelve-Step Facilitation (TSF) showed significantly fewer heavy drinking days and fewer alcohol-related consequences at post-treatment, 1-year, and 3-year follow-ups compared to those attending only 0–2 sessions ^[6]. At 3-year follow-up from the COMBINE trial, four distinct recovery profiles emerged, with both individual social determinants of health (lower education, lower income) and community-level factors (lower insurance rates, greater income inequality) associated with lower-functioning profiles ^[7].

Longer-term outcomes (8+ years): In a cohort of 395 previously untreated individuals followed for 8 years, extended family relationship quality at baseline and AA meeting attendance in the first three years independently predicted remission, lower depression, and better relationship quality at follow-up. Inpatient treatment days showed no independent association with long-term remission ^[8]. This finding does not argue against treatment — it argues for the importance of social and community resources alongside or after treatment.

Long-term relapse: Among people who had achieved at least one year of remission, long-term relapse frequently involved lowered recovery vigilance, psychological stressors, and shifts in support services. Participants attributed their relapse to a median of four contributing factors across multiple domains ^[9]. This multi-factor picture reinforces the chronic disease framing: relapse is not caused by one thing, and it is not prevented by one thing.

A critical gap: The corpus contains no longitudinal data tracking natural recovery trajectories beyond 8 years, and no repeated-measures data on the durability or mechanisms of untreated recovery. Available population-level data describe improvement at a single point in time, not a guaranteed individual trajectory ^[1]. Clinicians should use such figures to communicate hope and reduce stigma — not to defer treatment referral.

Lapse vs. Relapse — A Distinction That Changes Everything

One of the most clinically consequential distinctions in AUD recovery is the difference between a lapse and a relapse — and one of the most common clinical errors is treating them as the same thing.

A lapse is a single episode of drinking. A relapse is a sustained return to problematic drinking patterns. Most lapses do not become relapses. During the COVID-19 pandemic — a period of extraordinary stress — mild relapse events were reported by only approximately 3% of people in recovery, suggesting that recovery stability is achievable even under significant external pressure ^[10].

The mechanism connecting lapses to full relapse appears to involve negative emotion regulation. Research using cross-lagged panel models found that negative urgency — the tendency to act impulsively when distressed — showed bidirectional effects with all drinking outcomes (β = 0.09–0.18) from months 3 through 12 of a recovery attempt ^[11]. This means that a lapse can increase negative urgency, which increases the risk of further drinking — but this cycle is not inevitable, and it is interruptible.

For clinical practice, this means two things. First, framing a lapse as catastrophic failure can itself become a driver of full relapse — the "what the hell" effect. Second, a lapse is a clinical signal worth responding to, not ignoring. The appropriate response is re-engagement and support, not shame.

For patients and families, the message is: one drink is not the end of recovery. It is a moment that calls for attention and support.

Pathway Pluralism — Multiple Roads to Recovery

There is no single correct path to recovery from AUD. The evidence supports multiple pathways, and the question is not which pathway is best in the abstract — it is which pathway fits this person, at this point in their life.

Abstinence-focused pathways include Twelve-Step programs (AA, TSF), residential treatment, and medication-assisted treatment (MAT) aimed at supporting full abstinence. These have the strongest evidence base in the treatment literature. TSF and CBT both show dose-response effects on long-term outcomes ^[6], and AA attendance independently predicts 8-year remission in community samples ^[8].

Moderation-focused pathways include programs like Moderation Management and controlled drinking research. NESARC-III data show that 17.9% of people with prior AUD achieved non-abstinent low-risk recovery ^[1], and this group had markedly lower treatment receipt (12.3%) than abstinent recoverers. This suggests that moderation outcomes are real, common, and often achieved outside formal treatment.

Harm reduction pathways include managed drinking approaches and pharmacotherapy strategies like the Sinclair Method (targeted naltrexone use before drinking). These approaches prioritize reducing harm over achieving abstinence, and they engage people who might not otherwise seek help.

Spiritually integrated and community-based pathways are particularly important in communities facing systemic barriers to formal care. In Black communities, recovery pathways frequently blend AA with religion and spirituality, with participants emphasizing the importance of both receiving and providing support as recovery progresses ^[3]. Systemic barriers — including beliefs that recovery was not possible and inadequate early support — contributed to delayed initiation and prolonged early-recovery cycles in these communities ^[3].

The honest clinical message: pathway matching matters. Imposing an abstinence-only framework on someone whose goal is moderation may reduce engagement. Offering only harm reduction to someone who needs structured abstinence support may be insufficient. The evidence supports flexibility, not dogma.

AUD Treatment in Criminal Justice Settings

AUD Treatment in Criminal Justice Settings

People involved in the criminal justice system — including those in drug courts, on probation or parole, or incarcerated — have the same right to evidence-based treatment for alcohol use disorder (AUD), sometimes called alcoholism or alcohol addiction, as anyone else. Yet this population faces a specific and well-documented risk: being funneled into a single treatment modality not because it is the best clinical fit, but because it is the only one available in that setting.

The American Society of Addiction Medicine (ASAM) has taken a clear position on this. ASAM endorses access to the full range of FDA-approved pharmacotherapies for AUD — naltrexone (oral and extended-release injectable), acamprosate, and disulfiram — in correctional and court-mandated settings. Restricting access to only one medication, or to no medication at all, is inconsistent with evidence-based care and with the standard of treatment that justice-involved individuals deserve.

The informed consent requirement. When a mandated treatment program offers only one pharmacotherapy option — for example, extended-release injectable naltrexone (brand name Vivitrol) because oral naltrexone, acamprosate, or other options are not available in that facility or jurisdiction — ASAM's position is that patients must be told this explicitly. A person entering a court-ordered program has a right to know:

• What FDA-approved treatment options exist for their condition
• Which options are and are not available in their current setting
• That the program's limitations reflect resource or policy constraints, not a clinical determination that other options are inferior for them personally

Without this disclosure, a person may complete a mandated program believing they received the full standard of care — when in fact they received whatever was logistically available. That is not informed consent. It is a structural constraint being passed off as a clinical recommendation.

Why this matters for recovery outcomes. Pathway pluralism is not just a philosophical position — it has practical consequences. Naltrexone, acamprosate, and disulfiram have different mechanisms, different side-effect profiles, and different evidence profiles for different patient subgroups. A person who does not respond to one medication may respond to another. Limiting access to a single option reduces the likelihood of finding an effective fit, particularly for people with complex medical histories or co-occurring conditions.

The chronic disease framing that applies throughout this article applies here too: justice-involved individuals with AUD are managing a chronic medical condition. Mandated treatment is an opportunity to connect them with effective, individualized care — not a reason to narrow their options.

A note on the evidence base. Rigorous outcome data specifically comparing AUD pharmacotherapy access in criminal justice settings versus community settings are limited. ASAM's position reflects clinical and ethical reasoning grounded in the broader pharmacotherapy evidence base, not a dedicated correctional-setting trial literature. Clinicians and program administrators working in these settings should consult ASAM's most current guidelines on pharmacotherapy access in correctional and court-mandated contexts for specific implementation guidance.

WHO Risk Drinking Levels as Outcomes

There is a meaningful shift underway in how clinical trials measure success in AUD treatment ^[12]. Rather than treating abstinence as the only meaningful endpoint, researchers are increasingly using WHO Risk Drinking Level reductions as a primary outcome — and accumulating evidence supports this approach ^[12].

WHO Risk Drinking Levels categorize alcohol consumption from very high risk to abstinent. A person who moves from the "high risk" category to the "moderate risk" category has achieved a clinically meaningful change, even if they have not stopped drinking entirely.

This matters for several reasons. It expands the definition of treatment success. It makes treatment more accessible to people who are not ready or willing to pursue abstinence. And it aligns clinical measurement with the lived reality that many people's recovery involves gradual reduction rather than immediate cessation.

For clinicians, this means that a patient who reduces their drinking from very high risk to moderate risk has made meaningful progress worth acknowledging — even if they have not yet achieved the NIAAA recovery definition.

Maintenance Pharmacotherapy — How Long?

Pharmacotherapy for AUD is underused, and when it is used, it is often discontinued too soon. The evidence supports longer treatment durations than are commonly practiced.

Naltrexone has the strongest evidence base among AUD medications. Most trials support a minimum of 6 to 12 months of treatment, with some patients benefiting from longer duration. Naltrexone reduces heavy drinking days and craving, and its effects are most robust when combined with behavioral support.

Acamprosate shows similar duration recommendations, with evidence supporting continued use through the first year of sustained remission.

Disulfiram requires sustained adherence to maintain its deterrent effect. Unlike naltrexone and acamprosate, which work pharmacologically regardless of motivation, disulfiram's effectiveness depends on the patient's ongoing commitment to taking it — making adherence support a critical component of any disulfiram-based treatment plan.

Discontinuation decisions should be individualized. The chronic disease framing is relevant here: just as a person with hypertension does not stop antihypertensive medication because their blood pressure is currently controlled, a person in AUD recovery should not automatically discontinue pharmacotherapy because they are currently doing well. The question is not "are you better?" but "what is the risk of discontinuation?"

Note: The expert panel corpus did not include specific pharmacotherapy trial data beyond general references. The duration recommendations above reflect general clinical knowledge; clinicians should consult current guidelines for specific dosing and duration evidence.

Recovery Capital — The Resources That Make Recovery Possible

Recovery capital is one of the most important and underappreciated concepts in AUD treatment. It refers to the breadth and depth of internal and external resources a person can draw on to support their recovery.

The framework, developed by Granfield and Cloud, identifies four domains:
- Social capital: relationships, social networks, family support
- Human capital: education, employment, health, cognitive functioning
- Financial capital: income, housing stability, economic resources
- Community capital: access to recovery-supportive communities, institutions, and services

Higher recovery capital scores are associated with significantly greater odds of meeting NIAAA recovery criteria (OR = 1.61, p = .001) ^[13]. The relationship between recovery capital and outcomes varies by recovery duration, with different domains mattering more at different stages ^[13].

During the COVID-19 pandemic, recovery capital showed consistent protective effects against relapse, with adjusted odds ratios of 0.90 for women and 0.93 for men ^[10]. These are modest but meaningful effects, and they held up under conditions of significant external stress.

Community-level factors also matter. Lower community income, reduced health insurance coverage, and greater income inequality were all associated with lower-functioning recovery profiles at 3-year follow-up in the COMBINE study ^[7]. Recovery does not happen in a vacuum — it happens in neighborhoods, families, and economic systems that either support or undermine it.

The practical implication: treatment that focuses only on the individual and ignores their social and economic context is incomplete. Building recovery capital — through employment support, housing assistance, relationship repair, and community connection — is not a soft add-on to "real" treatment. It is a core component of sustained recovery.

Recovery Community Organizations

Recovery Community Organizations (RCOs) are peer-led, community-based organizations that provide recovery support services outside the clinical system. They are recognized by SAMHSA as a distinct and important component of the recovery support infrastructure.

Examples include Faces & Voices of Recovery and Young People in Recovery, both of which operate nationally and provide peer support, advocacy, and community connection. RCOs typically offer services including peer recovery coaching, recovery housing referrals, employment support, and community events that build recovery-supportive social networks.

Recovery support services (RSS) more broadly — including peer-based recovery support, recovery housing, and recovery community centers — are associated with decreased relapse rates, increased treatment engagement, and improved social support ^[14]. These effects are meaningful even when formal clinical interventions are limited.

An important gap: RCO-specific outcome research is methodologically challenging. RCOs serve diverse populations, operate in varied community contexts, and rarely have the resources to conduct randomized controlled trials. The evidence base is growing but remains less rigorous than treatment trial evidence. This does not mean RCOs are ineffective — it means the research infrastructure has not yet caught up with the practice.

Peer Recovery Support

Peer recovery support specialists — people with lived experience of AUD recovery who are trained and certified to support others — represent one of the most promising developments in the recovery support field.

Peer recovery coaching has been studied as a post-detox intervention, with evidence suggesting it can improve engagement and retention in recovery support ^[15]. Motivational enhancement approaches delivered by peers or clinicians post-detox also show promise for boosting early engagement ^[16].

Medicaid reimbursement for peer recovery support services has expanded significantly in recent years, making these services more accessible and sustainable. This policy shift reflects growing recognition that peer support is not a luxury — it is a cost-effective component of a comprehensive recovery support system.

The mechanism by which peer support works is not fully characterized in the current corpus. The most plausible pathways include social capital building, hope instillation (seeing someone who has recovered), practical problem-solving, and accountability — but these mechanisms require further research.

Sober Living and Recovery Housing

Recovery housing — including Oxford Houses and other transitional sober living environments — provides a structured, substance-free living environment that supports early recovery. It is a concrete form of recovery capital: stable, safe housing in a community of people committed to recovery.

The evidence base for recovery housing is modest but consistently positive on housing stability and recovery outcomes ^[14]. Oxford Houses, which are democratically run, self-supporting, and abstinence-based, have been studied more than most recovery housing models. Residents show lower relapse rates and better employment outcomes compared to those returning to their previous living situations.

Recovery housing is particularly important for people leaving residential treatment or incarceration, who face the highest relapse risk in the immediate post-discharge period. The transition from a structured treatment environment to an unstructured home environment — especially one that may include people who drink — is a high-risk moment that recovery housing can bridge.

Gap: The corpus contains limited direct evidence on sober living house models or RCO-led continuing care beyond general RSS categories ^[14]. Scaling recovery housing for underserved populations remains an evidence gap.

Re-Treatment After Relapse

Relapse is not failure of prior treatment. This point cannot be stated strongly enough, because the belief that relapse means treatment "didn't work" is one of the most damaging misconceptions in AUD care — for patients, families, and sometimes clinicians.

The chronic disease model of AUD is the appropriate frame here. Diabetes requires ongoing management. Hypertension requires ongoing management. When a person with diabetes has a period of poor glycemic control, we do not conclude that insulin therapy failed — we adjust the treatment plan. The same logic applies to AUD.

Long-term relapse after at least one year of remission involves multiple contributing factors across domains, with participants attributing their relapse to a median of four factors ^[9]. These factors include lowered recovery vigilance, psychological stressors, and changes in support services. This multi-factor picture means that re-treatment should be comprehensive — addressing not just the drinking but the conditions that contributed to the return.

Re-engagement protocols should be non-judgmental, rapid, and recovery-capital-informed. The question is not "why did you fail?" but "what changed, and what do you need now?" Prior treatment experience is itself a form of human capital — the person knows what helped before, what didn't, and what they would do differently.

Quality of Life and Functional Recovery

Recovery is not just about whether someone drinks. It is about whether they are living a life they value.

The shift from "recovery from" to "wellness in" recovery reflects a growing recognition that abstinence or reduced drinking is a means to an end, not the end itself. Employment recovery, housing stability, family relationship repair, physical health improvement, and mental health — these are the outcomes that matter most to people in recovery and their families.

Individual and partner predictors of 9-year outcomes in community samples include education, partner support, and prior treatment experiences ^[17]. Social and community resources — including AA attendance and extended family quality — predict 8-year remission and better psychosocial functioning more reliably than short-term professional treatment alone ^[8].

Recovery capital scores are associated not just with meeting NIAAA recovery criteria but with the broader quality-of-life dimensions that make recovery worth sustaining ^[13]. This reinforces the argument that treatment should be evaluated not only on drinking outcomes but on functional outcomes — employment, relationships, housing, health.

Gender differences in recovery experience and support use are also documented. Men show higher current digital recovery support use (9.9% vs. 5.8% in women) ^[18] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication), suggesting that recovery support services may need to be designed differently to reach women effectively.

Identity and Long-Term Recovery

One of the most important — and least clinically discussed — aspects of long-term recovery is identity transformation. For many people, sustained recovery involves not just stopping drinking but becoming a different kind of person: someone who no longer sees alcohol as central to their social life, coping strategies, or self-concept.

Research on identity transformation in recovery (Best, Granfield) suggests that long-term recovery often involves a fundamental reconstruction of self — building a recovery identity that is positive and forward-looking, not just defined by what one is abstaining from. Recovery becomes not the absence of drinking but the presence of a meaningful life.

This identity shift is supported by community connection, peer relationships, and meaningful activity — all components of recovery capital. It is also supported by mutual-help programs like AA, which provide a community of identity as well as practical support.

In Black communities, recovery pathways that integrate spirituality and religion alongside formal supports reflect a culturally grounded identity reconstruction that the broader recovery literature has underappreciated ^[3].

Gap: Identity transformation research is largely qualitative and not well-represented in the current corpus. The panel noted the absence of granular longitudinal accounts of identity shifts or pathway switching over decades. This is a genuine evidence gap, not a reason to dismiss the concept.

Mortality — Recovery Reduces Death Risk

AUD is a life-threatening condition. It is associated with liver disease, cardiovascular disease, cancer, accidents, suicide, and a substantially shortened life expectancy. Sustained remission reduces all-cause mortality — and this fact should be part of every clinical conversation about treatment urgency.

The magnitude of mortality reduction associated with sustained remission is clinically significant, particularly for patients with chronic medical comorbidities such as liver disease, cardiovascular disease, or diabetes. For these patients, the question of whether to pursue aggressive AUD treatment is not primarily about quality of life — it is about survival.

Gap: The expert panel corpus did not include specific mortality outcome data with quantified effect sizes. The epidemiologist on the panel explicitly noted that mortality outcomes were not quantified in the available documents. This is a significant gap in the corpus, and clinicians should consult dedicated mortality literature (e.g., studies of AUD-related mortality reduction with pharmacotherapy and sustained remission) for specific numbers.

Evidence Gaps — What We Still Don't Know

Honest science acknowledges its limits. The panel identified the following gaps that constrain what can be responsibly claimed:

1. Long-term natural recovery trajectories. The corpus documents that natural recovery happens at scale ^[19] but is largely silent on how it happens, for whom it is durable, and what distinguishes those who sustain it from those who deteriorate. Population-level improvement figures should be used to communicate hope and reduce stigma — not to defer treatment referral for individuals who need intervention ^[20].

2. Recovery capital in untreated vs. treated populations. The finding that recovery capital predicts NIAAA recovery (OR = 1.61) ^[13] does not stratify by treatment history. Whether recovery capital operates as a substitute for formal treatment, a complement to it, or differently across these groups is unknown from the current corpus.

3. Lapse-to-relapse transition data. The corpus does not characterize what proportion of single lapses escalate to full relapse, over what timeframe, or under what psychosocial conditions. This is precisely the data clinicians need to counsel patients responsibly about the difference between a slip and a sustained return to disorder.

4. 10+ year outcome data. Longitudinal data rarely exceed 3 years in the corpus, with the exception of the 8-year Humphreys cohort ^[8]. Decade-long recovery trajectories — including rates of late relapse, identity consolidation, and functional recovery — are not well-characterized.

5. RCO and recovery housing outcome research. Methodologically rigorous outcome data for recovery community organizations and sober living environments are limited. This reflects resource constraints in the field, not absence of effect.

6. Racial, ethnic, and socioeconomic moderators. Race and SES differences in recovery are addressed in select studies ^{[3] [7]} but lack meta-analytic synthesis. Pathway-matching research — identifying which interventions work best for which populations — is preliminary.

7. Mortality quantification. Specific effect sizes for mortality reduction associated with sustained AUD remission are absent from the corpus.

Summary for Clinical Practice

The evidence, taken together, supports the following clinical principles:

• Recovery is common. Most people with AUD improve over time, through multiple pathways, many without formal treatment ^[1]. This is a message of hope, not a reason to withhold treatment.

• Abstinence is not the only valid outcome. Non-abstinent low-risk recovery is real, common, and clinically meaningful ^{[3] [1]}.

• Lapse is not relapse. One drink does not undo recovery. The clinical response to a lapse is re-engagement, not catastrophizing ^[11].

• AUD is a chronic condition. Relapse is an expected feature of a chronic illness, not evidence that treatment failed. Re-treatment is appropriate, expected, and effective ^[9].

• Recovery capital matters as much as treatment modality. Social support, housing stability, employment, and community connection predict sustained recovery ^{[13] [8] [7]}. Treatment that ignores these factors is incomplete.

• Negative emotionality is a modifiable treatment target. Lower end-of-treatment negative emotionality predicts NIAAA recovery status ^[4]. Addressing emotion regulation during treatment is not a secondary concern — it is a primary one.

• Peer support and community infrastructure extend treatment gains. Recovery support services, peer coaching, and recovery housing are associated with reduced relapse and improved outcomes ^[21]. Linking patients to these resources after clinical treatment ends is a clinical responsibility.

Recovery is real. It is common. It takes many forms. And it is worth every effort to support.

This article was produced by synthesizing a multi-expert panel discussion grounded in verified research documents. All citations reflect papers cited by panel experts. Evidence quality varies by study design; meta-analytic and large cohort findings are weighted more heavily than single-study results. Identified evidence gaps are noted explicitly throughout.

Verified References

• ^[5] Behrendt, Silke, Kuerbis, Alexis, Braun-Michl, Barbara et al. (2021). "Residual alcohol use disorder symptoms after treatment predict long-term drinking outcomes in seniors with DSM-5 alcohol use disorder.". Alcohol Clin Exp Res. DOI: 10.1111/acer.14722 [abstract-verified: yes]
• ^[15] Byrne, Kaileigh A, Pericot-Valverde, Irene, Ross, Lesley A et al. (2025). "The Peer Recovery Coaching Linkage (RC-link) intervention study: Protocol for a randomized controlled trial for alcohol use disorder recovery in the inpatient hospital setting.". Contemp Clin Trials. DOI: 10.1016/j.cct.2025.108097 [abstract-verified: partial]
• ^[14] Day, Ed, Pechey, Laura Charlotte, Roscoe, Suzie et al. (2025). "Recovery support services as part of the continuum of care for alcohol or drug use disorders.". Addiction. DOI: 10.1111/add.16751 [abstract-verified: partial]
• ^[1] Fan, Amy Z, Chou, Sanchen Patricia, Zhang, Haitao et al. (2019). "Prevalence and Correlates of Past-Year Recovery From DSM-5 Alcohol Use Disorder: Results From National Epidemiologic Survey on Alcohol and Related Conditions-III.". Alcohol Clin Exp Res. DOI: 10.1111/acer.14192 [abstract-verified: yes]
• ^[11] Garber, Molly L, Belisario, Kyla L, Doggett, Amanda et al. (2026). "Relations between impulsivity and drinking in adults with alcohol use disorder during recovery: A longitudinal observational cohort study.". Alcohol Clin Exp Res (Hoboken). DOI: 10.1111/acer.70250 [abstract-verified: partial]
• ^[10] Gilbert, Paul A, Soweid, Loulwa, Kersten, Sarah K et al. (2021). "Maintaining recovery from alcohol use disorder during the COVID-19 pandemic: The importance of recovery capital.". Drug Alcohol Depend. DOI: 10.1016/j.drugalcdep.2021.109142 [abstract-verified: partial]
• ^[3] Hagman, Brett T, Falk, Daniel, Litten, Raye et al. (2022). "Defining Recovery From Alcohol Use Disorder: Development of an NIAAA Research Definition.". Am J Psychiatry. DOI: 10.1176/appi.ajp.21090963 [abstract-verified: partial]
• ^[8] Humphreys, K, Moos, R H, Cohen, C (1997). "Social and community resources and long-term recovery from treated and untreated alcoholism.". J Stud Alcohol. DOI: 10.15288/jsa.1997.58.231 [abstract-verified: yes]
• ^[9] Kelly, John F, Klein, Morgan, Zeng, Katherine et al. (2025). "Long-term relapse: markers, mechanisms, and implications for disease management in alcohol use disorder.". Front Public Health. DOI: 10.3389/fpubh.2025.1706192 [abstract-verified: yes]
• ^[13] LaBarre, Charles, Bowen, Elizabeth, Knapp, Kyler S (2025). "Recovery Capital Is Associated with a Greater Likelihood of NIAAA-Defined Recovery for Adults with Prior Alcohol Problems.". Subst Use Misuse. DOI: 10.1080/10826084.2025.2478598 [abstract-verified: partial]
• ^[4] Linn, B K, Zhao, J, Stasiewicz, P R et al. (2023). "Relationship of negative emotionality, NIAAA recovery, and 3- and 6-month drinking outcomes among adults in treatment for alcohol use disorder.". Drug Alcohol Depend. DOI: 10.1016/j.drugalcdep.2022.109695 [abstract-verified: yes]
• ^[17] Mary J McAweeney, Robert A Zucker, Hiram E Fitzgerald et al. (2005). "Individual and partner predictors of recovery from alcohol-use disorder over a nine-year interval: findings from a community sample of alcoholic married men.". Journal of studies on alcohol. DOI: 10.15288/jsa.2005.66.220 [abstract-verified: partial]
• ^[16] Naresh, D, Sivakumar, R Shreenithy, Logesh, D et al. (2026). "A Randomized Behavioral Intervention to Improve Outcomes Following Detoxification for Alcohol Dependence among Alcoholics.". Ann Afr Med. DOI: 10.4103/aam.aam_679_25 [abstract-verified: yes]
• ^[6] Pfund, Rory A, Hallgren, Kevin A, Maisto, Stephen A et al. (2021). "Dose of psychotherapy and long-term recovery outcomes: An examination of attendance patterns in alcohol use disorder treatment.". J Consult Clin Psychol. DOI: 10.1037/ccp0000703 [abstract-verified: partial]
• ^[7] Swan, Julia E, Aldridge, Arnie, Joseph, Verlin et al. (2021). "Individual and Community Social Determinants of Health and Recovery from Alcohol Use Disorder Three Years following Treatment.". J Psychoactive Drugs. DOI: 10.1080/02791072.2021.1986243 [abstract-verified: yes]
• ^[3] Vose-O'Neal, Adam, Christmas, Shanesha, Alfaro, Karen A et al. (2025). "Understanding pathways to recovery from alcohol use disorder in a Black community.". Front Public Health. DOI: 10.3389/fpubh.2025.1537059 [abstract-verified: yes]